Rivastigmine Tartrate

重酒石酸卡巴拉汀

Report date: 2026/05/25 20:02:40
NME

Base Information

Drug NameRivastigmine Tartrate
Drug Alias Name酒石酸利伐斯的明RivastigminumRivastigmina酒石酸利凡斯的明Exelon Patch +[24] 
ClassificationSmall molecules
Mechanisms of ActionAcetylcholinesterase inhibitorsButyrylcholinesterase inhibitors
TargetsAcetylcholinesteraseButyrylcholinesterase
Therapy Area/IndicationsCognition DisordersCocaine-Related DisordersSubstance-Related Disorders +[12] 
Global Approved IndicationsAlzheimer DiseaseDementiaParkinson Disease
Approved Indications in ChinaAlzheimer Disease
Original Approved Country/TerritoryEU
Original Approved Date1998/05/11
Country/TerritoryCzechiaBelgiumCanada +[37] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesEsteve Healthcare SLItalfarmacoExeltis Pharmaceuticals Holding SL +[12] 
Inactive CompaniesShahid Beheshti University Of Medical SciencesDuke UniversityNational Institute On Drug Abuse +[5] 
Active IndicationsAnticholinergic SyndromeAlzheimer DiseaseDementia +[4] 
Inactive IndicationsCognition DisordersCocaine-Related DisordersSubstance-Related Disorders +[8] 

Other Information

ATC CodeN06DA03
Related LinksWikipediaDrugBankKEGG